Rigvir Group finalised an ERAF funded project - GLP Toxicity Study of Rigvir

The aims of the project have been reached, and as a result a NOAEL (no adverse effect level) has been determined.

Rigvir Group participates in BIO-Europe Digital

Rigvir Group is participating in BIO-Europe Digital on October 26–29, 2020. Conference will be a fully digital event in the midst of the worldwide travel restrictions due to the global health emergency.

GMP compliance certificate received

Rigvir's new API (Active pharmaceutical ingredient) center of manufacturing has received GMP (Good Manufacturing Practice) compliance certification for the production of Rigvir virus ECHO-7.

A progressive stage IIIB melanoma treated with oncolytic ECHO-7 virus: A case report

Melanoma is an aggressive skin cancer form with a grave prognosis. Current results suggest that oncolytic virus treatment of melanoma has a high therapeutic potential.

Management of a primary malignant melanoma of uterine cervix stage IVA patient with radical surgery and adjuvant oncolytic virus Rigvir® therapy: A case report

Rigvir Group concludes a deal with Chinese biotech company Sinorda Biomedicine

Rigvir Group successfully attracted investments of EUR 500,000

The investment will be used in accordance with the Rigvir science program to strengthen the product's scientific capacity.

Adrenal Gland and Gastric Malignant Melanoma without Evidence of Skin Lesion Treated with the Oncolytic Virus Rigvir

Adrenal gland melanoma is an extremely rare diagnosis with less than 20 cases reported.

Effect of oncolytic ECHO-7 virus strain Rigvir on uveal melanoma cell lines

The results suggest cytolytic activity of oncolytic ECHO-7 virus strain Rigvir in MP41, 92-1 and Mel-202 cell lines.

Attention, counterfeit!

A counterfeit of medicine Rigvir has been detected, which is being distributed in Russia, Ukraine, Kazakhstan and possibly other countries. Counterfeit medicines are easily identifiable visually.

A Case Report published: ECHO-7 oncolytic virus Rigvir® in an adjuvant setting for stage I uveal melanoma

This report describes a stage I uveal melanoma patient treated with oncolytic virus Rigvir as an adjuvant therapy.

A Case Report published: Treatment of a stage III rima glottidis patient with the oncolytic virus Rigvir

This report describes a stage III glottic cancer patient treated with Rigvir therapy.

Rigvir Group is looking for partners globally

To finance the commercialization process of a next generation solution for unmet medical needs in oncology based on the existing product.

The Advent of Oncolytic Virotherapy in Oncology:
The Rigvir^® Story

Numerous viruses have been tested in clinical trials and three are approved. Our virus was the first.

Pioneers of Oncolytic Virotherapy with Biotechnological Focus

We are committed to prove, that the cancer treatment can be safe, effective and harmless.

We are Excited About the Future and Proud of Our Past

In the 1960s with the efforts of professor Aina Muceniece the focus points in the perception of cancer started to shift.

We Believe in the Good Virus

We invest in biomanufacturing and we focus on growing our portfolio of virotherapy medicines that meet the real needs of patients.

From Virotherapy Focus to Vision of Life Science

Innovations in biotechnological cancer treatments are the key concepts for improving the health quality of global population.